Inhibitory effects of Japanese herbal medicines sho-saiko-to and juzen-taiho-to on nonalcoholic steatohepatitis in mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Takahashi, Yoshihisa ^a   Soejima, Yurie ^a   Kumagai, Arisa ^a   Watanabe, Masato ^a   Uozaki, Hiroshi ^a   Fukusato, Toshio ^a  

^a TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; INCHINKO TO; INTERLEUKIN 6; KEISHI BUKURYO GAN; MALONALDEHYDE; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SHI QUAN DA BU TANG; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; XIAO CHAI HU TANG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEPATITIS; HERBAL MEDICINE; HISTOPATHOLOGY; LIVER FIBROSIS; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PROTEIN EXPRESSION;

ALANINE TRANSAMINASE; ANALYSIS OF VARIANCE; ANIMALS; DNA PRIMERS; DRUGS, CHINESE HERBAL; FATTY LIVER; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; LIVER; MEDICINE, KAMPO; MICE; PHYTOTHERAPY; PPAR GAMMA; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84899507684     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0087279     Document Type: Article

References (38)

1. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, et al. (1990) The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 11: 74-80. (Pubitemid 20075105)
2. Cohen JC, Horton JD, Hobbs HH (2011) Human fatty liver disease: old questions and new insights. Science 332: 1519-1523.
3. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al. (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37: 917-923. (Pubitemid 36397405)
4. Machado M, Cortez-Pinto H (2006) Non-alcoholic steatohepatitis and metabolic syndrome. Curr Opin Clin Nutr Metab Care 9: 637-642. (Pubitemid 44258042)
5. Day CP, James OF (1998) Steatohepatitis: a tale of two "hits"? Gastroenterology 114: 842-845.
6. Tilg H, Moschen AR (2010) Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52: 1836-1846.
7. Takahashi Y, Soejima Y, Fukusato T (2012) Animal models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 18: 2300-2308.
8. Motoo Y, Seki T, Tsutani K (2011) Traditional Japanese medicine, Kampo: its history and current status. Chin J Integr Med 17: 85-87.
9. Iizuka A, Iijima OT, Kondo K, Matsumoto A, Itakura H, et al. (2000) Antioxidative effects of Choi-oki-to and its ability to inhibit the progression of atheroma in KHC rabbits. J Atheroscler Thromb 6: 49-54.
10. Shiota G, Maeta Y, Mukoyama T, Yanagidani A, Udagawa A, et al. (2002) Effects of Sho-Saiko-to on hepatocarcinogenesis and 8-hydroxy-2′- deoxyguanosine formation. Hepatology 35: 1125-1133. (Pubitemid 34454009)
11. Nagai T, Nakao M, Shimizu Y, Kodera Y, Oh-ishi M, et al. (2011) Proteomic analysis of anti-inflammatory effects of a Kampo (Japanese herbal) medicine "Shoseiryuto (Xiao-qing-long-tang)" on airway inflammation in a mouse model. Evid Based Complement Alternat Med 2011: 604196.
12. Fujimoto M, Tsuneyama K, Kainuma M, Sekiya N, Goto H, et al. (2008) Evidence-based efficacy of Kampo formulas in a model of non alcoholic fatty liver. Exp Biol Med (Maywood) 233: 328-337. (Pubitemid 351328574)
13. Fujimoto M, Tsuneyama K, Kinoshita H, Goto H, Takano Y, et al. (2010) The traditional Japanese formula keishibukuryogan reduces liver injury and inflammation in patients with nonalcoholic fatty liver disease. Ann NY Acad Sci 1190: 151-158.
14. Sakaida I, Matsumura Y, Akiyama S, Hayashi K, Ishige A, et al. (1998) Herbal medicine Sho-saiko-to (TJ-9) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 28: 298-306. (Pubitemid 28116438)
15. Sakaida I, Tsuchiya M, Kawaguchi K, Kimura T, Terai S, et al. (2003) Herbal medicine Inchin-ko-to (TJ-135) prevents liver fibrosis and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. J Hepatol 38: 762-769. (Pubitemid 36613342)
16. Yamaoka K, Yamamoto Y, Ishii T (1990) The actual condition of use and quality control of the herb extract medicine. Byouin Yakugaku 16: 168-173. (in Japanese) (Pubitemid 20305209)
17. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, et al. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313-1321. (Pubitemid 40770284)
18. Mochiki E, Yanai M, Ohno T, Kuwano H (2010) The effect of traditional Japanese medicine (Kampo) on gastrointestinal function. Surg Today 40: 1105-1111.
19. Kusunose M, Qiu B, Cui T, Hamada A, Yoshioka S, et al. (2002) Effect of Sho-saiko-to extract on hepatic inflammation and fibrosis in dimethylnitrosamine induced liver injury rats. Biol Pharm Bull 25: 1417-1421. (Pubitemid 39663157)
20. Asakawa T, Yagi M, Tanaka Y, Asagiri K, Kobayashi H, et al. (2012) The herbal medicine Inchinko-to reduces hepatic fibrosis in cholestatic rats. Pediatr Surg Int 28: 379-384.
21. Yamashiki M, Mase A, Arai I, Huang XX, Nobori T, et al. (2000) Effects of the Japanese herbal medicine 'Inchinko-to' (TJ-135) on concanavalin A-induced hepatitis in mice. Clin Sci (Lond) 99: 421-431.
22. Tsuchiya M, Kono H, Matsuda M, Fujii H, Rusyn I (2008) Protective effect of Juzen-taiho-to on hepatocarcinogenesis is mediated through the inhibition of Kupffer cell-induced oxidative stress. Int J Cancer 123: 2503-2511.
23. Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, et al. (1996) Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84: 491-495. (Pubitemid 26060722)
24. Anstee QM, Goldin RD (2006) Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol 87: 1-16.
25. Leclercq IA, Farrell GC, Field J, Bell DR, Gonzalez FJ, et al. (2000) CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest 105: 1067-1075. (Pubitemid 30217691)
26. Chowdhry S, Nazmy MH, Meakin PJ, Dinkova-Kostova AT, Walsh SV, et al. (2010) Loss of Nrf2 markedly exacerbates nonalcoholic steatohepatitis. Free Radic Biol Med 48: 357-371.
27. Larter CZ, Yeh MM, Williams J, Bell-Anderson KS, Farrell GC (2008) MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol 49: 407-416.
28. Warren A, Bertolino P, Cogger VC, McLean AJ, Fraser R, et al. (2005) Hepatic pseudocapillarization in aged mice. Exp Gerontol 40: 807-812. (Pubitemid 41416543)
29. Ramadori G (1991) The stellate cell (Ito-cell, fat-storing cell, lipocyte, perisinusoidal cell) of the liver. New insights into pathophysiology of an intriguing cell. Virchows Arch B Cell Pathol Incl Mol Pathol 61: 147-158.
30. Younossi ZM, Stepanova M, Rafig N, Makhlouf H, Younoszai Z, et al. (2011) Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 53: 1874-1882.
31. Braunersreuther V, Viviani GL, Mach F, Montecucco F (2012) Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 18: 727-735.
32. Tailleux A, Wouters K, Staels B (2012) Roles of PPARs in NAFLD: potential therapeutic targets. Biochim Biophys Acta 1821: 809-818.
33. Bissell DM, Roulot D, George J (2001) Transforming growth factor beta and the liver. Hepatology 34: 859-867. (Pubitemid 33032019)
34. Shek FW, Benyon RC (2004) How can transforming growth factor beta be targeted usefully to combat liver fibrosis? Eur J Gastroenterol Hepatol 16: 123-126. (Pubitemid 39049646)
35. Guo HX, Liu DH, Ma Y, Liu JF, Wang Y, et al. (2009) Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol Sin 30: 1505-1512.
36. Qin S, Chen J, Tanigawa S, Hou DX (2012) Gene expression profiling and pathway network analysis of hepatic metabolic enzymes targeted by baicalein. J Ethnopharmacol 140: 131-140.
37. Tojima H, Yamazaki T, Tokudome T (1996) Two cases of pneumonia caused by Sho-saiko-to. Nihon Kyobu Shikkan Gakkai Zasshi 34: 904-910. (in Japanese). (Pubitemid 26307145)
38. Tomioka H, Hashimoto K, Ohnishi H, Fujiyama R, Sakurai T, et al. (1999) An autopsy case of interstitial pneumonia probably induced by Sho-saiko-to. Nihon Kokyuki Gakkai Zasshi 37: 1013-1018. (in Japanese).